Scribe Therapeutics has initiated a Phase 1 clinical trial of STX-1150, an epigenetic therapy that silences PCSK9 gene expression to reduce LDL cholesterol without permanent DNA modification. Preclinical data in primates demonstrated LDL reductions exceeding 50 percent sustained for approximately 18 months following a single dose, positioning epigenetic modulation as a potentially durable alternative to conventional lipid-lowering interventions.
Key Points
- Single-dose epigenetic therapy silences PCSK9 transcription without DNA alteration
- Preclinical sustained LDL reduction greater than 50% for 18 months
- Phase 1 trial enrolling up to 64 participants in Australia and New Zealand
Longevity Analysis
This trial represents a departure from permanent genetic modification toward transient epigenetic silencing—a distinction with significant implications for durability and safety. Cholesterol metabolism directly influences cardiovascular function and metabolic resilience; sustained reduction of LDL without genomic alteration could address a major driver of age-related vascular disease while preserving the cell's ability to respond dynamically to future environmental signals. The 18-month durability observed in primates suggests a potential shift from daily pharmaceutical compliance to infrequent administration, improving long-term treatment adherence and reducing cumulative pharmacological burden.
Original published by Longevity.Technology.